Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: Four mutations (rtS106C, rtD134N/S[N/S], rtM204V, and rtL269I) plus ETV resistance (rtL180M and rtS202G) existed when she developed viral breakthrough during ETV and TDF combination therapy in April 2013.
Abstract: Moreover, three mutations (rtS106C, rtD134N, and rtL269I) existed at baseline.
Entecavir resistance in a patient with treatment-naive HBV: A case report.
PMID: 33903819
2021
Molecular and clinical oncology
Discussion: There were 8 mutations in the RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V and rtM309K that were significantly associated with the progression of HCC in treatment-naive patients.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Conclusion: Eight mutations in RT reg
Method: Overall, eight mutations in the RT region, namely rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K, are significantly related to liver disease progression.
Table: D134E/N
Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients.
Discussion: The lamivudine resistance-linked G529A (rtD134N) site in HBV was found to be associated with HCC outcomes, which implied potential correlation between resistance to the anti-HBV nucleoside analog lamivudine and HCC prognosis.
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Figure: Some non-resistance-associated mutations of rtD134N (ranging from 20.33% to 74.63%), rtL145M (ranging from 2.83% to 78.82%),
Discussion: In addition to the common substitutions, some unknown amino acid substitutions, such as rtD134N, rtL145M/S, rtF151Y/L, rtR153Q, rtS223A, rtI224V, and rtN248H, need to be further verified.
Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.
Abstract: And the rtD134E/G/N/S mutations were also higher in chronic hepatitis B patients (22/100, 22.0%) and cirrhotic patients (21/100, 21.0%) than that in hepatocellular carcinoma patients (10/100, 10.0%, P = 0.021 and P = 0.032 respectively).
Result: Additionally, A significant portion of patients with
Discussion: And the rtS106C and rtD134E/G/N/S mutations may be associated with necro-inflammation, immune response and cirrhosis development in these treatment naive patients.
HBV mutation literature information.
PMID: 
2021
Hepatology research
Browser Board
Co-occurred Entities
Filtrator
ViMRT